A Safety Study of SYNT001 in Participants With Warm Autoimmune Hemolytic Anemia (WAIHA)
Study Identifier:
SYNT001-102
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Other
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: ALXN1830
Date
Jan 2018 - Apr 2019
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years
Requirements Information
Sex
Female & Male
Age
18+ years
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: ALXN1830
Date
Jan 2018 - Apr 2019
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years years
Requirements Information
Protocol Summary
This main study objective was to evaluate the safety and tolerability of intravenous (IV) SYNT001 (ALXN1830) in participants with WAIHA.
Trial Locations
Location
Status
Location
Alexion Study Site
Los Angeles, California, United States, 90033
Status
N/A
Location
Alexion Study Site
San Francisco, California, United States, 94143
Status
N/A
Location
Alexion Study Site
Boston, Massachusetts, United States, 02114
Status
N/A
Location
Alexion Study Site
Pittsfield, Massachusetts, United States, 01201
Status
N/A
Location
Alexion Study Site
Rochester, Minnesota, United States, 55905
Status
N/A
Location
Alexion Study Site
Cleveland, Ohio, United States, 44106
Status
N/A